Early phase trials of CD19 and BCMA CAR‐T in CNS autoimmune diseases (such as MG, NMOSD, and MS) reported only low‐grade CRS and rarely to no ICANS [84]. The gene discussed is CD19; the disease is myasthenia gravis.